Lerociclib
As of the edition of 20 October 2026, Lerociclib is a small molecule: stopped in 2025; acts on CDK4 and CDK6.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B and 2 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Lerociclib.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Lerociclib.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pharmacosmos | Lead sponsor of trials | 2016 to now |
| Revolution Medicines | Lead sponsor of trials | 2021 to now |